Teva Loses Status as Biggest Firm on TASE as Israelis Sue Too

Israeli institutional investors seeking class action in the U.S. estimate that price-fixing inflated Teva's profits by $2.3 billion

comments Print
A group of Israeli institutional investors has filed a motion to pursue a class action suit against Teva Pharmaceutical Industries, and some of its former executives, for allegedly colluding with other...